Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye
Citations Over TimeTop 10% of 2012 papers
Abstract
LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.
Related Papers
- → Plasma extravasation by chemical mediators in rat skin and trachea: A role of neurogenic agents on tracheal edema formation.(1989)12 cited
- → 5-Hydroxytryptamine-induced plasma extravasation in the rat knee joint is mediated by multiple prostaglandins(2003)11 cited
- → Observations in vivo on the extravasation of various dye fluids from blood vessels into the connective tissue(1964)6 cited
- → Multiple nitric oxide sources in neurogenic plasma extravasation in rat hindpaw skin(1998)6 cited